Investors Launch Class Action Against Valeant Pharmaceuticals In British Columbia:Lawsuit Seeks Compensation, Citing Oppresive Conduct And Misrepresentations
Investors Launch Class Action Against Valeant Pharmaceuticals In British Columbia:Lawsuit Seeks Compensation, Citing Oppresive Conduct And Misrepresentations
TORONTO, November 17, 2015 – Law firm Investigation Counsel Professional Corporation has commenced a class action in Vancouver on behalf of investors of Valeant Pharmaceuticals International Inc. (TSX: VRX-T), which is incorporated under the laws of British Columbia. The suit alleges oppression and securities violations by the company and certain of its directors and officers.
The claim arises from allegedly unlawful and improper business practices engaged in by Valeant and its agents to boost sales of the company’s expensive brand name drugs. Between September 28, 2015, and November 5, 2015, the price of the company’s shares dropped over 60%, a market loss of over $50 billion. The price of the company’s bonds also fell significantly during this period. These steep declines followed revelations of U.S. government investigations into Valeant’s pricing and business practices and disclosure of the company’s interest in a network of captive pharmacies. It is alleged that the company’s reputation has been damaged and its future business prospects have been severely prejudiced. Valeant’s investors have suffered substantial harm as a result.
The lawsuit has been brought on behalf of investors who purchased shares or bonds of Valeant between February 28, 2013, and October 21, 2015.
September 9, 2019
A proposed partial settlement has been reached with PricewaterhouseCoopers LLP on behalf of certain investors in the common shares and notes of Valeant Pharmaceuticals International Inc. A hearing to determine if the settlement will be approved will take place on November 11, 2019.
Settlement Long Form Notice and Opt Out Form (English)
Settlement Long Form Notice and Opt Out Form (French)
November 26, 2019
The Quebec Superior Court approved the settlement with PricewaterhouseCoopers LLP (Order available here) and plan of allocation (Order available here).
On December 5, 2019, in connection with the settlement approved by the Quebec Superior Court, the Ontario Superior Court of Justice approved a discontinuance of the Ontario proceedings and a dismissal of the claims against defendant PricewaterhouseCoopers LLP (court-approved Notice available here)
October 6, 2020
A proposed settlement that will finally resolve this litigation has been reached with Valeant Pharmaceuticals International Inc., the defendant officers and directors, and underwriters on behalf of certain investors in Valeant’s common shares and notes. A hearing to determine if the settlement will be approved will take place on November 16, 2020. Further details can be found in the notice linked below.
The Plan of Allocation can be found below:
November 26, 2020
The Quebec court has approved settlement that has been reached with Valeant Pharmaceuticals International Inc., the defendant officers and directors, and underwriters on behalf of certain investors in Valeant’s common shares and notes. Please find linked below copies of the short and long-form notices that explain the settlement, as well as the claim form which must be submitted to the settlement administrator in order to apply for compensation out of the settlement.
PLEASE NOTE: TO BE ELIGIBLE FOR COMPENSATION YOU MUST SUBMIT A CLAIM FORM TO THE ADDRESS AT THE TOP OF THE CLAIM FORM NO LATER THAN 11:59 PM (EASTERN TIME) ON FEBRUARY 15, 2021.
Long-Form Notice of Settlement Approval: ENGLISH FRENCH
Short-Form Notice of Settlement Approval: ENGLISH FRENCH
For more information, please contact John Archibald at jarchibald@investigationcounsel.com or use the contact form below.
TORONTO, November 17, 2015 – Law firm Investigation Counsel Professional Corporation has commenced a class action in Vancouver on behalf of investors of Valeant Pharmaceuticals International Inc. (TSX: VRX-T), which is incorporated under the laws of British Columbia. The suit alleges oppression and securities violations by the company and certain of its directors and officers.
The claim arises from allegedly unlawful and improper business practices engaged in by Valeant and its agents to boost sales of the company’s expensive brand name drugs. Between September 28, 2015, and November 5, 2015, the price of the company’s shares dropped over 60%, a market loss of over $50 billion. The price of the company’s bonds also fell significantly during this period. These steep declines followed revelations of U.S. government investigations into Valeant’s pricing and business practices and disclosure of the company’s interest in a network of captive pharmacies. It is alleged that the company’s reputation has been damaged and its future business prospects have been severely prejudiced. Valeant’s investors have suffered substantial harm as a result.
The lawsuit has been brought on behalf of investors who purchased shares or bonds of Valeant between February 28, 2013, and October 21, 2015.
September 9, 2019
A proposed partial settlement has been reached with PricewaterhouseCoopers LLP on behalf of certain investors in the common shares and notes of Valeant Pharmaceuticals International Inc. A hearing to determine if the settlement will be approved will take place on November 11, 2019.
Settlement Long Form Notice and Opt Out Form (English)
Settlement Long Form Notice and Opt Out Form (French)
November 26, 2019
The Quebec Superior Court approved the settlement with PricewaterhouseCoopers LLP (Order available here) and plan of allocation (Order available here).
On December 5, 2019, in connection with the settlement approved by the Quebec Superior Court, the Ontario Superior Court of Justice approved a discontinuance of the Ontario proceedings and a dismissal of the claims against defendant PricewaterhouseCoopers LLP (court-approved Notice available here)
October 6, 2020
A proposed settlement that will finally resolve this litigation has been reached with Valeant Pharmaceuticals International Inc., the defendant officers and directors, and underwriters on behalf of certain investors in Valeant’s common shares and notes. A hearing to determine if the settlement will be approved will take place on November 16, 2020. Further details can be found in the notice linked below.
The Plan of Allocation can be found below:
November 26, 2020
The Quebec court has approved settlement that has been reached with Valeant Pharmaceuticals International Inc., the defendant officers and directors, and underwriters on behalf of certain investors in Valeant’s common shares and notes. Please find linked below copies of the short and long-form notices that explain the settlement, as well as the claim form which must be submitted to the settlement administrator in order to apply for compensation out of the settlement.
PLEASE NOTE: TO BE ELIGIBLE FOR COMPENSATION YOU MUST SUBMIT A CLAIM FORM TO THE ADDRESS AT THE TOP OF THE CLAIM FORM NO LATER THAN 11:59 PM (EASTERN TIME) ON FEBRUARY 15, 2021.
Long-Form Notice of Settlement Approval:
Short-Form Notice of Settlement Approval:
Claim Form:
For more information, please contact John Archibald at jarchibald@investigationcounsel.com or use the contact form below.